Oxidative challenge in Alzheimer's disease: State of knowledge and future needs

Journal of Investigative Medicine

Volumn 64, Issue 1, 2016, Pages 21-32

  Cervellati, Carlo ^a   Wood, Paul L ^b   Romani, Arianna ^a   Valacchi, Giuseppe ^a,c   Squerzanti, Monica ^a   Sanz, Juana Maria ^a   Ortolani, Beatrice ^a   Zuliani, Giovanni ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b LINCOLN MEMORIAL UNIVERSITY   (United States)

^c Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; BIOLOGICAL MARKER; ANTIOXIDANT;

ALZHEIMER DISEASE; AUTOPSY; BLOOD; BRAIN TISSUE; CEREBROSPINAL FLUID; CLINICAL FEATURE; HUMAN; IN VIVO STUDY; LIPID PEROXIDATION; NEUROLOGIC DISEASE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; REVIEW; URINE; BIOLOGICAL MODEL; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; ANTIOXIDANTS; BIOMARKERS; HUMANS; MODELS, BIOLOGICAL; OXIDATIVE STRESS;

EID: 84980019075     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.1136/jim-2015-000017     Document Type: Review

References (161)

1. Ott A, Breteler MM, van Harskamp F, et al. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ 1995;310:970-3.
2. Parihar MS, Hemnani T. Alzheimer's disease pathogenesis and therapeutic interventions. J Clin Neurosci 2004;11:456-67.
3. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol 1997;82:291-5.
4. Chen L, Na R, Gu M, et al. Lipid peroxidation up-regulates BACE1 expression in vivo: a possible early event of amyloidogenesis in Alzheimer's disease. J Neurochem 2008;107:197-207.
5. Praticò D, Uryu K, Leight S, et al. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 2001;21:4183-7.
6. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004;3:205-14.
7. Butterfield DA, Swomley AM, Sultana R. Amyloid p-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid Redox Signal 2013;19:823-35.
8. Dalle-Donne I, Rossi R, Colombo R, et al. Biomarkers of oxidative damage in human disease. Clin Chem 2006;52:601-23.
9. Lesko LJ, Atkinson AJ. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001;41:347-66.
10. Di Domenico F, Coccia R, Butterfield DA, et al. Circulating biomarkers of protein oxidation for Alzheimer disease: expectations within limits. Biochim Biophys Acta 2011;1814:1785-95.
11. Farina N, Isaac MG, Clark AR, et al. Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database Syst Rev 2012;11: CD002854.
12. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-88.
13. Serrano-Pozo A, Frosch MP, Masliah E, et al. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011;1:a006189.
14. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999;45:358-68.
15. Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-28.
16. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 2011;7:280-92.
17. Dickerson BC, Goncharova I, Sullivan MP, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging 2001;22:747-54.
18. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009;73:294-301.
19. Misra C, Fan Y, Davatzikos C. Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI. Neuroimage 2009;44:1415-22.
20. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-94.
21. Markesbery WR, Schmitt FA, Kryscio RJ, et al. Neuropathologic substrate of mild cognitive impairment. Arch Neurol 2006;63:38-46.
22. Jack CR, Petersen RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000;55:484-9.
23. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-5.
24. Swerdlow RH. Pathogenesis of Alzheimer's disease. Clin Interv Aging 2007;2:347-59.
25. Maccioni RB, Farías G, Morales I, et al. The revitalized tau hypothesis on Alzheimer's disease. Arch Med Res 2010;41:226-31.
26. Swerdlow RH, Khan SM. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med Hypotheses 2004;63:8-20.
27. de la Torre JC. Pathophysiology of neuronal energy crisis in Alzheimer's disease. Neurodegener Dis 2008;5:126-32.
28. de la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 2004;3:184-90.
29. Winkler EA, Nishida Y, Sagare AP, et al. GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci 2015;18:521-30.
30. Kosenko EA, Solomadin IN, Tikhonova LA, et al. Pathogenesis of Alzheimer disease: role of oxidative stress, amyloid-p peptides, systemic ammonia and erythrocyte energy metabolism. CNS Neurol Disord Drug Targets 2014;13:112-19.
31. Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39:44-84.
32. Aliev G, Priyadarshini M, Reddy VP, et al. Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer disease. Curr Med Chem 2014;21:2208-17.
33. Aliev G, Obrenovich ME, Tabrez S, et al. Link between cancer and Alzheimer disease via oxidative stress induced by nitric oxide-dependent mitochondrial DNA overproliferation and deletion. Oxid Med Cell Longev 2013;2013:962984.
34. Keisari Y, Braun L, Flescher E. The oxidative burst and related phenomena in mouse macrophages elicited by different sterile inflammatory stimuli. Immunobiology 1983;165:78-89.
35. Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 2000;279:L1005-28.
36. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000;18:655-73.
37. Bergamini CM, Gambetti S, Dondi A, et al. Oxygen, reactive oxygen species and tissue damage. Curr Pharm Des 2004;10:1611-26.
38. Grimm S, Hoehn A, Davies KJ, et al. Protein oxidative modifications in the ageing brain: consequence for the onset of neurodegenerative disease. Free Radic Res 2011;45:73-88.
39. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem 2005;12:1161-208.
40. Borges F, Fernandes E, Roleira F. Progress towards the discovery of xanthine oxidase inhibitors. Curr Med Chem 2002;9:195-217.
41. Cadenas E, Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 2000;29:222-30.
42. Carr AC, McCall MR, Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol 2000;20:1716-23.
43. Carreras MC, Pargament GA, Catz SD, et al. Kinetics of nitric oxide and hydrogen peroxide production and formation of peroxynitrite during the respiratory burst of human neutrophils. FEBS Lett 1994;341:65-8.
44. McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 1969;244:6049-55.
45. Cadenas E. Basic mechanisms of antioxidant activity. Biofactors 1997;6:391-7.
46. Pastor N, Weinstein H, Jamison E, et al. A detailed interpretation of OH radical footprints in a TBP-DNA complex reveals the role of dynamics in the mechanism of sequence-specific binding. J Mol Biol 2000;304:55-68.
47. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis 2000;21:361-70.
48. Forman HJ, Davies KJ, Ursini F. How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo. Free Radic Biol Med 2014;66:24-35.
49. Swartz HM, Khan N, Khramtsov VV Use of electron paramagnetic resonance spectroscopy to evaluate the redox state in vivo. Antioxid Redox Signal 2007;9:1757-71.
50. Kohen R, Nyska A. Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol 2002;30:620-50.
51. Kadiiska MB, Gladen BC, Baird DD, et al. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med 2005;38:698-710.
52. Kadiiska MB, Peddada S, Herbert RA, et al. Biomarkers of oxidative stress study VI. Endogenous plasma antioxidants fail as useful biomarkers of endotoxin-induced oxidative stress. Free Radic Biol Med 2015;81:100-6.
53. Pryor WA. Oxidative stress status: OSS, BOSS, and "Wild Bill" Donovan. Free Radic Biol Med 1999;27:1135-6.
54. Block G, Dietrich M, Norkus EP, et al. Factors associated with oxidative stress in human populations. Am J Epidemiol 2002;156:274-85.
55. Keaney JF, Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: Clinical correlates of oxidative stress in the Framingham study. Arterioscler Thromb Vasc Biol 2003;23:434-9.
56. Cervellati C, Bonaccorsi G, Cremonini E, et al. Accumulation of central fat correlates with an adverse oxidative balance in non-obese postmenopausal women. Gynecol Endocrinol 2013;29:1063-6.
57. Trevisan M, Browne R, Ram M, et al. Correlates of markers of oxidative status in the general population. Am J Epidemiol 2001;154:348-56.
58. Pou KM, Massaro JM, Hoffmann U, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: The Framingham Heart Study. Circulation 2007;116:1234-41.
59. Cervellati C, Bonaccorsi G, Cremonini E, et al. Waist circumference and dual-energy X-ray absorptiometry measures of overall and central obesity are similarly associated with systemic oxidative stress in women. Scand J Clin Lab Investig 2014;74:102-7.
60. Skoumalová A, Hort J. Blood markers of oxidative stress in Alzheimer's disease. J Cell Mol Med 2012;16:2291-300.
61. Teunissen CE, de Vente J, Steinbusch HW, et al. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging 2002;23:485-508.
62. de Zwart LL, Meerman JH, Commandeur JN, et al. Biomarkers of free radical damage applications in experimental animals and in humans. Free Radic Biol Med 1999;26:202-26.
63. Liu J, Yeo HC, Doniger SJ, et al. Assay of aldehydes from lipid peroxidation: gas chromatography-mass spectrometry compared to thiobarbituric acid. Anal Biochem 1997;245:161-6.
64. Moselhy HF, Reid RG, Yousef S, et al. A specific, accurate, and sensitive measure of total plasma malondialdehyde by HPLC. J Lipid Res 2013;54:852-8.
65. Carini M, Aldini G, Facino RM. Mass spectrometry for detection of 4-hydroxy-trans-2-nonenal (HNE) adducts with peptides and proteins. Mass Spectrom Rev 2004;23:281-305.
66. Weber D, Milkovic L, Bennett SJ, et al. Measurement of HNE-protein adducts in human plasma and serum by ELISA-Comparison of two primary antibodies. Redox Biol 2013;1:226-33.
67. Milne GL, Gao B, Terry ES, et al. Measurement of F2-isoprostanes and isofurans using gas chromatography-mass spectrometry. Free Radic Biol Med 2013;59:36-44.
68. Forman HJ, Augusto O, Brigelius-Flohe R, et al. Even free radicals should follow some rules: a guide to free radical research terminology and methodology. Free Radic Biol Med 2015;78:233-5.
69. Ho E, Karimi Galougahi K, Liu CC, et al. Biological markers of oxidative stress: applications to cardiovascular research and practice. Redox Biol 2013;1:483-91.
70. Davies MJ, Fu S, Wang H, et al. Stable markers of oxidant damage to proteins and their application in the study of human disease. Free Radic Biol Med 1999;27:1151-63.
71. Alamdari DH, Kostidou E, Paletas K, et al. High sensitivity enzyme-linked immunosorbent assay (ELISA) method for measuring protein carbonyl in samples with low amounts of protein. Free Radic Biol Med 2005;39:1362-7.
72. Cheng KC, Cahill DS, Kasai H, et al. 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G--T and A--C substitutions. J Biol Chem 1992;267:166-72.
73. Evans MD, Olinski R, Loft S, et al. Toward consensus in the analysis of urinary 8-oxo-7, 8-dihydro-2-deoxyguanosine as a noninvasive biomarker of oxidative stress. FASEB J 2010;24:1249-60.
74. Cuajungco MP, Goldstein LE, Nunomura A, et al. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem 2000;275:19439-42.
75. Du Y, Wooten MC, Gearing M, et al. Age-associated oxidative damage to the p62 promoter: implications for Alzheimer disease. Free Radic Biol Med 2009;46:492-501.
76. Mangialasche F, Polidori MC, Monastero R, et al. Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Res Rev 2009;8:285-305.
77. Butterfield DA, Reed TT, Perluigi M, et al. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res 2007;1148:243-8.
78. Butterfield DA, Poon HF, St Clair D, et al. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: Insights into the development of Alzheimer's disease. Neurobiol Dis 2006;22:223-32.
79. Markesbery WR, Kryscio RJ, Lovell MA, et al. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol 2005;58:730-5.
80. Schrag M, Mueller C, Zabel M, et al. Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: a meta-analysis. Neurobiol Dis 2013;59:100-10.
81. Cervellati C, Cremonini E, Bosi C, et al. Systemic oxidative stress in older patients with mild cognitive impairment or late onset Alzheimer's disease. Curr Alzheimer Res 2013;10:365-72.
82. Montine TJ, Quinn JF, Milatovic D, et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol 2002;52:175-9.
83. Sinem F, Dildar K, Gökhan E, et al. The serum protein and lipid oxidation marker levels in Alzheimer's disease and effects of cholinesterase inhibitors and antipsychotic drugs therapy. Curr Alzheimer Res 2010;7:463-9.
84. Mufson EJ, Leurgans S. Inability of plasma and urine F2A-isoprostane levels to differentiate mild cognitive impairment from Alzheimer's disease. Neurodegener Dis 2010;7:139-42.
85. Bonda DJ, Wang X, Perry G, et al. Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology 2010;59:290-4.
86. Smith MA, Richey Harris PL, Sayre LM, et al. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997;17:2653-7.
87. Praticò D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Ann N Y Acad Sci 2008;1147:70-8.
88. Cai Z, Zhao B, Ratka A. Oxidative stress and β-amyloid protein in Alzheimer's disease. Neuromolecular Med 2011;13:223-50.
89. Bading JR, Yamada S, Mackic JB, et al. Brain clearance of Alzheimer's amyloid-beta40 in the squirrel monkey: a SPECT study in a primate model of cerebral amyloid angiopathy. J Drug Target 2002;10:359-68.
90. Lehner C, Gehwolf R, Tempfer H, et al. Oxidative stress and blood-brain barrier dysfunction under particular consideration of matrix metalloproteinases. Antioxid Redox Signal 2011;15:1305-23.
91. Golden TR, Hinerfeld DA, Melov S. Oxidative stress and aging: beyond correlation. Aging Cell 2002;1:117-23.
92. Richardson JR, Roy A, Shalat SL, et al. Elevated serum pesticide levels and risk for Alzheimer disease. JAMA Neurol 2014;71:284-90.
93. Wiener HW, Perry RT, Chen Z, et al. A polymorphism in SOD2 is associated with development of Alzheimer's disease. Genes Brain Behav 2007;6:770-5.
94. Morris JK, Honea RA, Vidoni ED, et al. Is Alzheimer's disease a systemic disease? Biochim Biophys Acta 2014;1842:1340-9.
95. Kaminsky YG, Reddy VP, Ashraf GM, et al. Age-related defects in erythrocyte 2, 3-diphosphoglycerate metabolism in dementia. Aging Dis 2013;4:244-55.
96. Dias-Santagata D, Fulga TA, Duttaroy A, et al. Oxidative stress mediates tau-induced neurodegeneration in Drosophila. J Clin Invest 2007;117:236-45.
97. Wilkinson BL, Landreth GE. The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J Neuroinflammation 2006;3:30.
98. Abramov AY, Canevari L, Duchen MR. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci 2004;24: 565-75.
99. Yan SD, Stern DM. Mitochondrial dysfunction and Alzheimer's disease: role of amyloid-beta peptide alcohol dehydrogenase (ABAD). Int J Exp Pathol 2005;86:161-71.
100. Mao P, Reddy PH. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: implications for early intervention and therapeutics. Biochim Biophys Acta 2011;1812:1359-70.
101. Zhao Y, Zhao B. Oxidative stress and the pathogenesis of Alzheimer's disease. Oxid Med Cell Longev 2013;2013:316523.
102. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997;23:134-47.
103. Keller JN, Schmitt FA, Scheff SW, et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 2005;64:1152-6.
104. Bermejo P, Martín-Aragón S, Benedí J, et al. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment. Free Radic Res 2008;42:162-70.
105. Calabrese V, Sultana R, Scapagnini G, et al. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal 2006;8:1975-86.
106. Aldred S, Bennett S, Mecocci P. Increased low-density lipoprotein oxidation, but not total plasma protein oxidation, in Alzheimer's disease. Clin Biochem 2010;43:267-71.
107. Baldeiras I, Santana I, Proença MT, et al. Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease. J Alzheimers Dis 2008;15:117-28.
108. Dorszewska J, Kempisty B, Jaroszewska-Kolecka J, et al. Expression and polymorphisms of gene 8-oxoguanine glycosylase 1 and the level of oxidative DNA damage in peripheral blood lymphocytes of patients with Alzheimer's disease. DNA Cell Biol 2009;28:579-88.
109. Mecocci P, Polidori MC, Cherubini A, et al. Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch Neurol 2002;59:794-8.
110. Dezor M, Dorszewska J, Florczak J, et al. Expression of 8-oxoguanine DNA glycosylase 1 (OGG1) and the level of p53 and TNF-αlpha proteins in peripheral lymphocytes of patients with Alzheimer's disease. Folia Neuropathol 2011;49:123-31.
111. Abe T, Tohgi H, Isobe C, et al. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease. J Neurosci Res 2002;70:447-50.
112. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994;36:747-51.
113. Wang J, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J Neurochem 2006;96:825-32.
114. Yao Y, Zhukareva V, Sung S, et al. Enhanced brain levels of 8, 12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia. Neurology 2003;61:475-8.
115. Praticò D, MY Lee V, Trojanowski JQ, et al. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 1998;12:1777-83.
116. Montine TJ, Peskind ER, Quinn JF, et al. Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer's disease as identified by biomarkers. Neuromolecular Med 2011;13:37-43.
117. Montine KS, Quinn JF, Zhang J, et al. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids 2004;128:117-24.
118. Praticò D, Clark CM, Lee VM, et al. Increased 8, 12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 2000;48:809-12.
119. Roberts LJ, Montine TJ, Markesbery WR, et al. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 1998;273:13605-12.
120. Aybek H, Ercan F, Aslan D, et al. Determination of malondialdehyde, reduced glutathione levels and APOE4 allele frequency in late-onset Alzheimer's disease in Denizli, Turkey. Clin Biochem 2007;40:172-6.
121. Puertas MC, Martínez-Martos JM, Cobo MP, et al. Plasma oxidative stress parameters in men and women with early stage Alzheimer type dementia. Exp Gerontol 2012;47:625-30.
122. Martín-Aragón S, Bermejo-Bescós P, Benedí J, et al. Metalloproteinase's activity and oxidative stress in mild cognitive impairment and Alzheimer's disease. Neurochem Res 2009;34:373-8.
123. Torres LL, Quaglio NB, de Souza GT, et al. Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2011;26:59-68.
124. Cervellati C, Romani A, Seripa D, et al. Oxidative balance, homocysteine, and uric acid levels in older patients with Late Onset Alzheimer's Disease or Vascular Dementia. J Neurol Sci 2014;337:156-61.
125. Serra JA, Domínguez RO, Marschoff ER, et al. Systemic oxidative stress associated with the neurological diseases of aging. Neurochem Res 2009;34:2122-32.
126. Lovell MA, Ehmann WD, Butler SM, et al. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 1995;45:1594-601.
127. McGrath LT, McGleenon BM, Brennan S, et al. Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM 2001;94:485-90.
128. Sultana R, Perluigi M, Allan Butterfield D. Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain. Free Radic Biol Med 2013;62:157-69.
129. Butterfield DA, Reed T, Perluigi M, et al. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett 2006;397:170-3.
130. Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 1998;19:33-6.
131. Cervellati C, Romani A, Seripa D, et al. Systemic oxidative stress and conversion to dementia of elderly patients with mild cognitive impairment. Biomed Res Int 2014;2014:309507.
132. Montine TJ, Markesbery WR, Morrow JD, et al. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol 1998;44:410-13.
133. Bucossi S, Ventriglia M, Panetta V, et al. Copper in Alzheimer's disease: a meta-analysis of serum, plasma, and cerebrospinal fluid studies. J Alzheimers Dis 2011;24:175-85.
134. Squitti R, Lupoi D, Pasqualetti P, et al. Elevation of serum copper levels in Alzheimer's disease. Neurology 2002;59:1153-61.
135. Gilca M, Lixandru D, Gaman L, et al. Erythrocyte membrane stability to hydrogen peroxide is decreased in Alzheimer disease. Alzheimer Dis Assoc Disord 2014;28:358-63.
136. Zuliani G, Ranzini M, Guerra G, et al. Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia. J Psychiatr Res 2007;41:686-93.
137. Polidori MC, Mecocci P. Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease. J Alzheimers Dis 2002;4:517-22.
138. Sticozzi C, Cervellati F, Muresan XM, et al. Resveratrol prevents cigarette smoke-induced keratinocytes damage. Food Funct 2014;5: 2348-56.
139. Li Y, Cao Z, Zhu H. Upregulation of endogenous antioxidants and phase 2 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle cells leads to cytoprotection against oxidative and electrophilic stress. Pharmacol Res 2006;53:6-15.
140. Kosenko EA, Aliev G, Tikhonova LA, et al. Antioxidant status and energy state of erythrocytes in Alzheimer dementia: probing for markers. CNS Neurol Disord Drug Targets 2012;11:926-32.
141. Charlton-Menys V, Liu Y, Durrington PN. Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrate. Clin Chem 2006;52:453-7.
142. Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998;101:1581-90.
143. Shih DM, Xia YR, Wang XP, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000;275:17527-35.
144. Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008;299:1265-76.
145. Bednarska-Makaruk ME, Krzywkowski T, Graban A, et al. Paraoxonase 1 (PON1) gene-108C>T and p.Q192R polymorphisms and arylesterase activity of the enzyme in patients with dementia. Folia Neuropathol 2013;51:111-19.
146. Pi Y, Zhang L, Chang K, et al. Lack of an association between Paraoxonase 1 gene polymorphisms (Q192R, L55M) and Alzheimer's disease: a meta-analysis. Neurosci Lett 2012;523:174-9.
147. La Du BN, Eckerson HW. The polymorphic paraoxonase/arylesterase isozymes of human serum. Fed Proc 1984;43:2338-41.
148. Wehr H, Bednarska-Makaruk M, Graban A, et al. Paraoxonase activity and dementia. J Neurol Sci 2009;283:107-8.
149. Zengi O, Karakas A, Ergun U, et al. Urinary 8-hydroxy-2-deoxyguanosine level and plasma paraoxonase 1 activity with Alzheimer's disease. Clin Chem Lab Med 2012;50:529-34.
150. Cervellati C, Romani A, Bergamini CM, et al. PON-1 and ferroxidase activities in older patients with mild cognitive impairment, late onset Alzheimer's disease or vascular dementia. Clin Chem Lab Med 2015;53:1049-56.
151. Sultana R, Butterfield DA. Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. J Bioenerg Biomembr 2009;41:441-6.
152. Martinelli N, Girelli D, Olivieri O, et al. Novel serum paraoxonase activity assays are associated with coronary artery disease. Clin Chem Lab Med 2009;47:432-40.
153. Draganov D, Teiber J, Watson C, et al. PON1 and oxidative stress in human sepsis and an animal model of sepsis. Adv Exp Med Biol 2010;660:89-97.
154. Commenges D, Scotet V, Renaud S, et al. Intake of flavonoids and risk of dementia. Eur J Epidemiol 2000;16:357-63.
155. Luchsinger JA, Tang MX, Shea S, et al. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60:203-8.
156. Engelhart MJ, Geerlings MI, Ruitenberg A, etal. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002;287: 3223-9.
157. Wood PL, Khan MA, Kulow SR, etal. Neurotoxicity of reactive aldehydes: The concept of "aldehyde load" as demonstrated by neuroprotection with hydroxylamines. Brain Res 2006;1095:190-9.
158. Morris MC, Evans DA, Tangney CC, et al. Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. Am J Clin Nutr 2005;81:508-14.
159. Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol 2011;81:337-44.
160. Bocci V, Valacchi G. Nrf2 activation as target to implement therapeutic treatments. Front Chem 2015;3:4.
161. Zhu H, Itoh K, Yamamoto M, et al. Role of Nrf2 signaling in regulation of antioxidants and phase 2 enzymes in cardiac fibroblasts: Protection against reactive oxygen and nitrogen species-induced cell injury. FEBS Lett 2005;579:3029-36.